KPTI

SEC source: 0001209191-17-040536 · doc4.xml · derivative · entry 1

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2027-06-14

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date.

SEC source: 0001209191-17-040565 · doc4.xml · derivative · entry 1

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2027-06-14

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date.

SEC source: 0001209191-17-040548 · doc4.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2027-06-14

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on June 15, 2018, provided that the holder continues to serve as a director of the issuer through such date.

SEC source: 0001209191-17-005325 · doc4.xml · derivative · entry 1

Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2027-01-19

F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-17-005322 · doc4.xml · derivative · entry 2

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2027-01-19

F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-17-005322 · doc4.xml · derivative · entry 1

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2027-01-19

F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-17-005327 · doc4.xml · derivative · entry 1

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2027-01-19

F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-17-005326 · doc4.xml · derivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · SVP, OPS, BUS DEV, GC & SEC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,000

Underlying: Common Stock · 118,000 shares

Expires 2027-01-19

F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-17-005323 · doc4.xml · derivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2027-01-19

F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-17-005323 · doc4.xml · derivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2027-01-19

F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-16-150139 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,691

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.05 to $10.13, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-16-149852 · doc4.xml · nonDerivative · entry 1

Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,173

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 8, 2016 and November 9, 2016 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-16-149846 · doc4.xml · nonDerivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · SVP,CORP DEV,GEN COUNSEL&SEC.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,819

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 8, 2016 and November 9, 2016 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-16-148845 · doc4.xml · derivative · entry 2

Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-16-148845 · doc4.xml · nonDerivative · entry 1

Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F2 · balance_after: Includes 3,515 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.

SEC source: 0001209191-16-148848 · doc4.xml · derivative · entry 2

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F2 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F2 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-16-148848 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

SEC source: 0001209191-16-148843 · doc4.xml · derivative · entry 2

Primiano Christopher Brett · CIK 0001603510 · SVP,CORP DEV,GEN COUNSEL&SEC.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-16-148843 · doc4.xml · nonDerivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · SVP,CORP DEV,GEN COUNSEL&SEC.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F2 · balance_after: Includes 4,161 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.